PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Phenotype | C0028754|obesity |
| Sentences | 83 |
| PubMedID- 23867312 | Background & aims: the development and progression of non-alcoholic fatty liver disease are associated with aging, obesity, and type 2 diabetes. |
| PubMedID- 25841911 | Majority of cases of hcc are due to chronic viral hepatitis b and c infections; however non-alcoholic fatty liver disease, associated with obesity and diabetes emerges as an important risk factor for hcc, in particular in the developed countries. |
| PubMedID- 20186137 | Nonalcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance, and impaired glucose tolerance. |
| PubMedID- 26423886 | The liver is a critical organ for regulation of energy homeostasis and fatty liver disease is closely associated with obesity and insulin resistance. |
| PubMedID- 25591123 | Morbid obesity is strongly associated with nonalcoholic fatty liver disease (nafld), which is one of the most common causes of chronic liver disease worldwide. |
| PubMedID- 26341254 | Aim: nonalcoholic fatty liver disease (nafld) is associated with obesity and affects roughly 10% of children. |
| PubMedID- 25490708 | Elevated ggt can signal liver injury generally, and non-alcoholic fatty liver disease associated with abdominal obesity and other features of the metabolic syndrome [39]. |
| PubMedID- 26098416 | Furthermore, insulin resistance as well as overall obesity could be features of nonalcoholic fatty liver disease, and the ob/ob mice in our study, as previously known display increased triglycerides in the liver. |
| PubMedID- 24269922 | Iron deficiency in patients with nonalcoholic fatty liver disease is associated with obesity, female gender, and low serum hepcidin. |
| PubMedID- 25278764 | Non-alcoholic fatty liver disease (nafld) leads to obesity and type 2 diabetes.10,11 hepatic tg content in nafld is directly related to the free fatty acid uptake by liver. |
| PubMedID- 24737534 | Background: morbid obesity is strongly associated with nonalcoholic fatty liver disease. |
| PubMedID- 22364559 | obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. |
| PubMedID- 22720061 | Non-alcoholic fatty liver disease is associated with obesity and considered an inflammatory disease. |
| PubMedID- 24335764 | Objective: fatty liver disease is commonly associated with obesity, insulin resistance and diabetes. |
| PubMedID- 25921668 | Diabetes and obesity are associated with nonalcoholic fatty liver disease (nafld) and an increased incidence of hepatocellular carcinoma (hcc). |
| PubMedID- 25278690 | Viral hepatitis, alcohol abuse, and exposure to hepatotoxins are major risk factors, but nonalcoholic fatty liver disease (nafld) associated with obesity, insulin resistance, and type 2 diabetes, is an increasingly recognized trigger, especially in developed countries. |
| PubMedID- 26223028 | In developed countries such as united states, nonalcoholic fatty liver disease (nafld), associated with obesity, are thought to account for the majority of hcc [4–6]. |
| PubMedID- 25897319 | This results in liver fibrosis, which is a major cause of mortality worldwide mainly because of chronic infection with the hepatitis virus and obesity associated with fatty liver disease [1]. |
| PubMedID- 25484079 | Nonalcoholic fatty liver disease (nafld), typically associated with overnutrition and obesity, is one of the most common liver diseases both in the us and worldwide. |
| PubMedID- 23995473 | In addition, in obesity, an increased prevalence of nonalcoholic fatty liver disease and reduced cardiorespiratory fitness are observed. |
| PubMedID- 26394730 | Metabolic health is more important than obesity in the development of non-alcoholic fatty liver disease: a four-year retrospective study. |
| PubMedID- 23113121 | Nafld is a common liver disease strongly associated with obesity, type 2 diabetes mellitus and hyperlipidemia (2). |
| PubMedID- 24397808 | Fatty liver disease associated with obesity is an important medical problem and the mechanisms for lipid accumulation in hepatocytes are not fully elucidated yet. |
| PubMedID- 21325464 | Introduction: triglyceride accumulation in the liver is an early feature in the development of nonalcoholic fatty liver disease (nafld) associated with human obesity, which is a multifactorial syndrome and whose underlying mechanisms are beginning to be understood. |
| PubMedID- 22110414 | Due to a progressive increase in the prevalence of nonalcoholic fatty liver disease (nafld) associated with ‘endemic’ obesity, overlapped nafld, especially in its necroinflammatory form of nonalcoholic steatohepatitis (nash), has gained clinical relevance in the diagnosis and prognosis of chronic liver disease. |
| PubMedID- 19882375 | Background: although nonalcoholic fatty liver disease (nafld) is associated with visceral obesity, the relationship between visceral fat accumulation and skeletal muscle steatosis in patients with nafld has not been established. |
| PubMedID- 25905166 | Furthermore, serum igf-i levels decline with normal aging, and tend to be low in obesity and in patients with non-alcoholic fatty liver disease. |
| PubMedID- 20509914 | Non-alcoholic steatohepatitis (nash) is a form of liver disease associated with obesity, and is characterized by the accumulation of lipid droplets in the cytoplasm of hepatocytes, mixed cell type inflammation, necrosis and often may involve some degree of fibrosis. |
| PubMedID- 25797622 | Ob/ob mice provide an animal model for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (nafld/nash) in patients with obesity and type-2 diabetes. |
| PubMedID- 22768831 | Although obesity is associated with nonalcoholic fatty liver disease (nafld), the causal mechanisms are unclear. |
| PubMedID- 24395145 | Questions have also been raised about the appropriateness of the body mass index (bmi) for assessing obesity in patients with end-stage liver disease. |
| PubMedID- 23800945 | Background: obesity-induced liver disease (nonalcoholic fatty liver disease, nafld) is now the commonest cause of chronic liver disease in affluent nations. |
| PubMedID- 22561686 | Fatty liver disease is associated with obesity and type 2 diabetes, and hepatic lipid accumulation may contribute to insulin resistance. |
| PubMedID- 25663786 | Aim: to investigate whether central obesity is associated with nonalcoholic fatty liver disease (nafld) formation after adjusting for general obesity. |
| PubMedID- 20221393 | Background: non-alcoholic steatohepatitis (nash) is a serious form of non-alcoholic fatty liver disease (nafld), associated with obesity and insulin resistance. |
| PubMedID- 25854973 | The prevalence of cld differs between countries, affecting approximately 300 million people in china,1 29 million in the european union2 and more than 8 million cases in australia.3 the leading causes of cld are viral hepatitis b and c (hcv), harmful alcohol consumption and metabolic fatty liver disease associated with obesity and type 2 diabetes.1–7 regardless of aetiology, most of the morbidity and mortality from cld occurs among individuals with cirrhosis, who are at risk of developing complications including ascites, hepatic encephalopathy, variceal haemorrhage and liver cancer. |
| PubMedID- 23721199 | This is particularly important because, although the obesity-related incidence of fatty liver disease continues to rise, no effective treatments are currently available[49]. |
| PubMedID- 23939604 | Nonalcoholic fatty liver disease is associated with physical inactivity, obesity, and metabolic syndrome. |
| PubMedID- 25885415 | Although obesity increases the risk of fatty liver disease, hepatic fat accumulation can also develop in non-obese individuals [1,2]. |
| PubMedID- 22876713 | Conclusions: in our series, there was a high prevalence of ld, being fatty liver disease associated with obesity the most frequent finding. |
| PubMedID- 25790917 | Conclusion: our investigations show that in fatty liver disease in combination with obesity and diabetes, the hepatocyte-protecting organelle peroxisome is altered. |
| PubMedID- 25644347 | Background: nonalcoholic fatty liver disease is positively associated with obesity and cardiovascular disease risk. |
| PubMedID- 23390441 | Purpose: childhood obesity is associated with nonalcoholic fatty liver disease (nafld), and it has become one of the most common causes of childhood chronic liver diseases which significant as a cause of liver related mortality and morbidity in children in the united states. |
| PubMedID- 25922835 | However, the role of resistin in obesity associated with fatty liver disease remains controversial [17–19]. |
| PubMedID- 24460705 | Conclusions: visceral obesity is associated with non-alcoholic fatty liver disease (nafld) and nash: we hypothesized that these conditions can influence adamts13 antigen and activity. |
| PubMedID- 26157696 | Fatty liver disease has been associated with obesity in children [918]. |
| PubMedID- 20188144 | Background: non-alcoholic fatty liver disease (nafld) is associated with obesity, insulin resistance and hepatic steatosis. |
| PubMedID- 24713801 | Background: although non-alcoholic fatty liver disease (nafld) is associated with obesity and metabolic syndrome (ms), it may also be present in lean individuals. |
| PubMedID- 20197789 | Background/objectives: nonalcoholic fatty liver disease is commonly associated with obesity, insulin resistance, dyslipidemia and type 2 diabetes, and can thus be regarded as the hepatic manifestation of metabolic syndrome. |
| PubMedID- 23181558 | Non-alcoholic fatty liver disease is strongly associated with both obesity and type 2 diabetes [2]. |
Page: 1 2